Headquartered in Salt Lake City, UT Fiscal year ends December NASDAQ: MYGN myriad.com
Myriad Genetics is a molecular diagnostic and precision medicine company that develops and commercializes genetic tests across oncology, prenatal health, and mental health. Its Cancer Care Continuum portfolio includes hereditary cancer risk assessment (MyRisk, BRACAnalysis CDx), tumor profiling (MyChoice CDx, Precise Tumor), minimal residual disease monitoring (Precise MRD), and prostate cancer prognostics (Prolaris + AI). The Prenatal Health segment offers carrier screening (Foresight), non-invasive prenatal testing (Prequel), the FirstGene Multiple Prenatal Screen, and consumer gender testing (SneakPeek). The Mental Health segment is anchored by GeneSight, a pharmacogenomic test that helps clinicians optimize medication selection for patients with depression and other psychiatric conditions. The company serves healthcare providers across the United States and is traded on NASDAQ under the ticker MYGN. Updated
Wednesday's top analyst upgrades and downgrades included Chevron, Cleveland-Cliffs, Infosys, Knight-Swift Transportation, Microsoft, Nucor, Salesforce, Steel Dynamics, Wheaton Precious Metals and Zoom Video Communications.
Thursday's top analyst upgrades and downgrades included Adobe, Apple, Conagra Brands, CrowdStrike, Fortinet, IBM, Mobileye Global, Morgan Stanley, Oatly, Oracle, PayPal, Seagate Technology, Shopify and Williams Companies.
Friday's top analyst upgrades and downgrades included Airbnb, Cleveland-Cliffs, CrowdStrike, Meta Platforms, Nasdaq, Okta, PENN Entertainment, PPL, Splunk, Target, U.S. Steel and Zscaler.
Friday's top analyst upgrades and downgrades included Applied Materials, Autodesk, Bank of America, BP, Broadcom, Micron Technology, Morgan Stanley and Western Digital.
Alliance Data, Cimarex Energy, Myriad Genetics and Nestle were among Tuesday afternoon's analyst upgrades and downgrades.
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Boston Beer, Carvana, HD Supply, Marathon Petroleum, Square, Trade Desk and Whirlpool.
The top analyst upgrades, downgrades and initiations for Wednesday included Acorda Therapeutics, Activision Blizzard, Bloom Energy, Care.com, CBS, Deere and Ferrari.
The top analyst upgrades, downgrades and initiations seen on Thursday included AbbVie, Agilent Technologies, Albermarle, Apple, Boeing, Cheniere Energy, First Solar, HCA, LabCorp, Lumber Liquidators and Teva Pharmaceutical.
The top analyst upgrades, downgrades and initiations seen on Wednesday include Agilent Technologies, Alibaba, CRISPR Therapeutics, Iridium Communications, McDonald's, Myriad Genetics, Shake Shack and Take-Two Interactive Software.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Baker Hughes, CBS, Generac, Halliburton, Nike, PG&E, Snap, Tesla, Weatherford and Western Digital.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Amazon, Apple, BP, CSX, General Electric, Humana, Myriad Genetics, Mondelez, UnitedHealth and Vodafone.
The top analyst upgrades, downgrades and initiations seen on Tuesday include Affimed, Coty, Cree, Lululemon Athletica, Myriad Genetics, Tesla and Xilinx.
The top analyst upgrades, downgrades and initiations seen from Wednesday include AT&T, CenturyLink, MercadoLibre, Netflix, Starbucks, Tiffany, TJX Companies and YRC Worldwide.
The top analyst upgrades, downgrades and other research calls from Wednesday include AT&T, Comcast, Hess, Netflix, Petrobras, Sirius XM, Texas Instruments, Verizon and Walt Disney.
The top analyst upgrades, downgrades and other research calls from Wednesday include Applied Materials, Celgene, Children's Place, Kinder Morgan, Match, Myriad Genetics, Nordstrom and Oracle.
Myriad Genetics is a molecular diagnostic and precision medicine company that develops and commercializes genetic tests across oncology, prenatal health, and mental health.
The Wall Street consensus 12-month price target for MYGN is $4.11.
